Giant Cell Myocarditis in a Patient With Crohn's Disease, Treated with Etanercept – A Tumour Necrosis Factor-Alpha Antagonist
Cardiac disease in association with inflammatory bowel disease (IBD) is uncommon. Reports include pericarditis, pericardial effusion, myocarditis, myocardial infarction, endocarditis and arrythmias. Myocardial inflammation related to IBD may be due to a drug hypersensitivity reaction or micronutrien...
Main Authors: | C Nash, R Panaccione, LR Sutherland, JB Meddings |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2001-01-01
|
Series: | Canadian Journal of Gastroenterology |
Online Access: | http://dx.doi.org/10.1155/2001/954340 |
Similar Items
-
CARDIOPROTECTIVE EFFECT OF TUMOR NECROSIS FACTOR ALPHA ANTAGONIST IN DOXORUBICIN MYOCARD TOXICITY
by: M. I. Popovich, et al.
Published: (2018-02-01) -
Canadian Association of Gastroenterology Clinical Practice Guidelines: The Use of Tumour Necrosis Factor-Alpha Antagonist Therapy in Crohn’s Disease
by: Daniel C Sadowski, et al.
Published: (2009-01-01) -
Serum tumor necrosis factor alpha increased during remission with Etanercept
by: Miu Nicolae, et al.
Published: (2011-09-01) -
A Life-Threatening Abscess in a Patient Treated with a Tumour Necrosis Factor-Alpha Antagonist: A Case Report
by: Dieter Cadosch, et al.
Published: (2009-08-01) -
Studies on ovine tumour necrosis factor alpha
by: Green, Ian R.
Published: (1994)